Peptonic Medical AB (publ) ("Peptonic" or the "Company") announces that the Board of Directors has postponed the Annual General Meeting and the publication of the annual report for 2025. The annual report will be published on June 3, 2026 and the Annual General Meeting will be held on June 24, 2026.
Previously communicated dates according to the Company's financial calendar were the publication of the annual report on May 20, 2026 and the Annual General Meeting on June 10, 2026. The postponement is due to administrative reasons.
For further information, please contact:
Daniel Rudeklint, acting CEO, Peptonic Medical AB
Email: daniel.rudeklint@peptonicmedical.se
Telephone: +46 73 158 02 73
About Peptonic Medical AB
Peptonic Medical AB (publ) is a Swedish medical device company that develops and sells clinically proven self-care products for women's intimate health. Under the VagiVital and Vernivia brands, the Company offers a non-prescription portfolio of effective and gentle products that help women understand, treat and prevent common gynaecological conditions. Peptonic's growth strategy is based on geographical expansion, particularly in the US and Europe, and on continuously strengthening the product portfolio through in-house product development and strategic acquisitions.
The Company has its headquarters in Stockholm, Sweden, and subsidiaries Peptonic Medical Inc. and Common Sense Marketing Inc. in the US. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.